SCHEMBL5418647

SCHEMBL5418647

CNc1nc(Nc2ccccc2Cl)ncc1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.59
▸ GSK3B P49841 2/20 0.55
▸ LRRK2 Q5S007 6/20 0.54
▸ ALDH1A1 P00352 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ ULK1 O75385 1/20 0.52
▸ PIN1 Q13526 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ PLK1 P53350 1/20 0.48
▸ AURKA O14965 2/20 0.47
▸ GSK3A P49840 1/20 0.47
▸ PRKCQ Q04759 4/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413325 0.86 LRRK2 (0.62) IGF1RGSK3BLRRK2MAPK1HTT
SCHEMBL5408522 0.83 LRRK2 (0.65) IGF1RGSK3BLRRK2ALDH1A1LMNA
SCHEMBL5413522 0.82 PTK2 (0.54) IGF1RGSK3BLRRK2ALDH1A1ULK1
SCHEMBL5402268 0.82 GSK3B (0.82) IGF1RGSK3BLRRK2ALDH1A1LMNA
SCHEMBL5408180 0.80 STK17A (0.66) GSK3BLRRK2LMNAMAPK1PIN1
SCHEMBL5410032 0.79 GSK3B (0.54) GSK3BLRRK2PIN1JAK2PLK1
SCHEMBL5405462 0.79 STK17A (0.51) IGF1RGSK3BLRRK2PRKCQMEN1
SCHEMBL5419322 0.79 GSK3B (0.53) IGF1RGSK3BLRRK2LMNAMAPK1
SCHEMBL5413375 0.78 PRKCQ (0.64) IGF1RGSK3BLRRK2PIN1JAK2
SCHEMBL1521779 0.78 GSK3B (0.53) GSK3BLMNAPIN1PLK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 IGF1R 1724/4885GSK3B 1515/4885LRRK2 619/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 IGF1R 1986/4885GSK3B 790/4885LRRK2 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback